Vistagen Therapeutics (VTGN) Receivables - Other (2019 - 2023)

Vistagen Therapeutics (VTGN) posted Receivables - Other of $380000.0 for Q2 2023, up 763.64% sequentially from $44000.0 in Q2 2021.

Vistagen Therapeutics (VTGN) Receivables - Other (2019 - 2023) Analysis & Trends

Vistagen Therapeutics has reported Receivables - Other for 3 years, with the latest figure at $380000.0 in Q2 2023.

Quarterly Receivables - Other changed N/A year-over-year to $380000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $380000.0 (changed N/A YoY) and the FY2021 annual result came in at $40600.0, up 113.53% from the prior year.
Receivables - Other improved to $380000.0 in Q2 2023 per VTGN's latest filing, from $44000.0 in the prior quarter.
Over five years, Receivables - Other peaked at $380000.0 in Q2 2023 and troughed at -$300000.0 in Q2 2019.
A 3-year average of $92920.0 and a median of $44000.0 in 2021 frame the typical range for Receivables - Other.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.66 Bn	131.80 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.52 Bn	78.53 Bn	3.93 Bn
3	Argenx Se	65.33 Bn	60.14 Bn	1.37 Bn
4	Moderna	59.76 Bn	54.62 Bn	52.00 Mn
5	BeOne Medicines	42.15 Bn	37.05 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.84 Bn	28.53 Bn	992.69 Mn
7	BioNTech SE	28.23 Bn	9.84 Bn	668.28 Mn
8	Insmed	27.52 Bn	26.36 Bn	358.27 Mn
9	Royalty Pharma	27.29 Bn	26.46 Bn	-
10	Vistagen Therapeutics	10.50 Mn	10.50 Mn	-

Download Data